written on 28.04.2014

US Capitol Capsule: Rare disease sector matures; FDA keeping pace?


Companies developing drugs to treat rare diseases – traditionally the biotechs – have matured as a sector, and now it's time for them to "really get comfortable in that skin," because increasingly more attention is being paid to the…

Latest Report